IBI-306
Hypercholesterolemia
NDA SubmittedActive
Key Facts
About Innovent Biologics
Innovent Biologics' mission is to develop and commercialize high-quality, innovative medicines that are affordable and accessible to patients worldwide. Its key achievements include a successful 2018 Hong Kong IPO, the commercialization of multiple blockbuster products like Tyvyt® (sintilimab), and the establishment of a deep, diversified pipeline through internal R&D and strategic partnerships. The company's strategy hinges on full integration, global expansion, and leveraging its robust technology platforms to deliver a sustainable portfolio of novel biologics.
View full company profileTherapeutic Areas
Other Hypercholesterolemia Drugs
| Drug | Company | Phase |
|---|---|---|
| VXX-401 | Vaxxinity | Phase 1 |
| Atorvastatin Oral Liquid Suspension | CMP Pharma | Approved |
| AFFITOPE® AT04 (licensed to Frontier Biotech) | AFFiRiS | Phase 1 |
| AQR-008 | Aqur Biosciences | Pre-clinical |
| Leqvio® (inclisiran) | Novartis | Approved |
| MK-0616 | Merck | Phase 3 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase III |
| Inusiran (AK102) | Akeso | Approved |
| Obicetrapib + Ezetimibe FDC | NewAmsterdam Pharma Company | Phase 3 |